HAE
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trading at a discount to growth potential despite being above defensive fair value.
- PEG < 1.0
- Forward P/E is low (11.43)
- Price well below Intrinsic Value
- Price exceeds Graham Number
Growth is currently driven by margin expansion and cost efficiency rather than sales growth.
- Strong earnings acceleration
- Positive analyst target price ($84.60)
- Negative YoY and Q/Q revenue growth
Operational success has not yet translated into long-term share price appreciation.
- Consistent EPS beats over 25 quarters
- Strong recovery in 6-month price performance (+18.1%)
- Poor 3Y and 5Y total returns
Strong liquidity and improving financial strength metrics.
- Piotroski F-Score 7/9
- Current Ratio 1.75
- Quick Ratio 1.04
- Debt/Equity 1.34
Company is not returning capital via dividends.
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HAE and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corporation
Primary
|
-11.4% | -27.8% | -3.5% | +18.1% | +11.9% | -1.1% |
|
TARS
Tarsus Pharmaceuticals, Inc.
Peer
|
+124.0% | +341.3% | +36.0% | -7.3% | +2.3% | -9.2% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
|
CON
Concentra Group Holdings Parent, Inc.
Peer
|
+3.3% | +3.3% | +8.6% | +9.8% | +3.7% | -0.2% |
|
TXG
10x Genomics, Inc.
Peer
|
-88.0% | -57.2% | +199.1% | +76.3% | +20.0% | -7.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corporation
|
BULLISH | $2.81B | 16.66 | 19.3% | 13.3% | $60.48 | |
|
TARS
Tarsus Pharmaceuticals, Inc.
|
NEUTRAL | $2.81B | - | -23.4% | -14.7% | $65.97 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
|
CON
Concentra Group Holdings...
|
NEUTRAL | $2.93B | 17.55 | 48.1% | 7.7% | $22.82 | Compare |
|
TXG
10x Genomics, Inc.
|
NEUTRAL | $2.93B | - | -5.8% | -6.8% | $22.97 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-10 | KROLL MARK W | Director | Purchase | 1,400 | $98,784 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning HAE from our newsroom.